ישראל -
עברית -
Ministry of Health
אוקסרבט
mind pharma europe ltd. - cenegermin - טיפות עיניים - cenegermin 20 mcg / 1 ml - cenegermin
ישראל -
עברית -
Ministry of Health
germaine de capuccini-פילינג גרגירים לפנים
כהן זהבית - ניקוי הפנים
ישראל -
עברית -
Ministry of Health
בסרמי 250 מקג 0.5 מל
aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 500 mcg/ml - ropeginterferon alfa-2b
ישראל -
עברית -
Ministry of Health
בסרמי 500 מקג 0.5 מל
aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 1000 mcg/ml - ropeginterferon alfa-2b
ישראל -
עברית -
Ministry of Health
סבוסל
taro pharmaceutical industries ltd - selenium sulfide - תרחיף - selenium sulfide 25 mg/ml - selenium sulfide - selenium sulfide - for the treatment of dandruff, seborrheic dermatitis of the scalp and tinea versicolor.
ישראל -
עברית -
Ministry of Health
קלינרלsebo קרם פנים מרגיע לעור הפנים
אהבה - מעבדות ים המלח בעמ - הזנה לפנים
ישראל -
עברית -
Ministry of Health
קלינרלsebo ג'ל ניקוי לפנים
אהבה - מעבדות ים המלח בעמ - ניקוי הפנים
ישראל -
עברית -
Ministry of Health
אקסטביה
novartis pharma services ag - interferon beta 1b 0.3 mg - powder and solvent for solution for injection - interferon beta-1b - extavia is indicated for the treatment of:• for use in relapsing-remitting and relapsing-progressive multiple sclerosis. it is designated for ambulatory patients who meet criteria for clinically definite and for laboratory supported definite ms, and who have experienced at least two exacerbations over the last two years.extavia reduces the frequency of clinical exacerbations.in secondary progressive multiple sclerosis extavia is indicated for slowing progression of disease and for the reduction of frequency of clinical relapses. compared with placebo, patients receiving extavia showed a statistically significant delay in time to progression of multiple sclerosis. the treatment effect occurred in patients with and without relapses and at all levels of disability investigated (patients with mild disease and those unable to walk were not studied). patients receiving extavia also showed a statistically significant delay in the time to become wheelchair-bound when compared with placebo. see also section 5.1 “pharm
ישראל -
עברית -
Ministry of Health
טלזנה 0.25 מג
pfizer pharmaceuticals israel ltd - talazoparib as tosylate - קפסולה קשיחה - talazoparib as tosylate 0.25 mg - talazoparib